HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia.

AbstractBACKGROUND:
Both aripiprazole and haloperidol have been used in the treatment of schizophrenia, and are metabolized by the cytochrome P450 (CYP) 2D6 and CYP3A4. The authors studied the correlations between the steady-state plasma concentrations (Css) of aripiprazole and its active metabolite, dehydroaripiprazole, and those of haloperidol in 19 Japanese patients with schizophrenia, together with the effects of CYP2D6 genotypes on the steady-state kinetics of these compounds.
METHODS:
All the patients received first 24 mg/d of aripiprazole for 3 weeks and later received 6 mg/d of haloperidol for 2 weeks. Blood samplings were performed at least 2 weeks after the initiation of each treatment. The Css values of aripiprazole and dehydroaripiprazole were measured using liquid chromatography with mass spectrometric detection, and those of haloperidol were measured by using an enzyme immunoassay. CYP2D6 genotypes were determined by using polymerase chain reaction analysis.
RESULTS:
None of the correlations between the Css of aripiprazole (r = 0.286) or the sum of aripiprazole plus dehydroaripiprazole (r = 0.344) and those of haloperidol were significant. The mean Css of aripiprazole was significantly higher (P < 0.05) in the subjects with 1 *10 allele of CYP2D6 (n = 6) than in those with no mutated alleles (n = 13), whereas there were no significant differences in those of haloperidol between the 2 groups.
CONCLUSIONS:
This study suggests that the Css of aripiprazole and that of aripiprazole plus dehydroaripiprazole do not correlate with that of haloperidol in the same individual, because of the greater involvement of CYP2D6 in the metabolism of aripiprazole than in that of haloperidol.
AuthorsAkifumi Nakamura, Kazuo Mihara, Kenji Nemoto, Goyo Nagai, Shoko Kagawa, Takeshi Suzuki, Tsuyoshi Kondo
JournalTherapeutic drug monitoring (Ther Drug Monit) Vol. 36 Issue 6 Pg. 815-8 (Dec 2014) ISSN: 1536-3694 [Electronic] United States
PMID24739668 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antipsychotic Agents
  • Piperazines
  • Quinolones
  • Aripiprazole
  • Haloperidol
Topics
  • Adult
  • Antipsychotic Agents (blood, therapeutic use)
  • Aripiprazole
  • Asian People (genetics)
  • Female
  • Haloperidol (blood, therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Piperazines (blood, therapeutic use)
  • Quinolones (blood, therapeutic use)
  • Schizophrenia (blood, drug therapy, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: